The treatment of patients with low tumour burden and/or slow growing disease.
In the evaluation of the wide range of novel therapeutics which have been developed, investigators do not have to be tied to the current paradigm of demonstrating additive efficacy to first line combination therapy. The addition of new agents to FOLFOX regimens has proved a high hurdle at which many...
| 第一著者: | |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
2011
|